{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:00Z","timestamp":1787026620799,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the risk of incident uveitis among patients with axial spondyloarthritis initiating treatment with Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an emulated target trial using real-world electronic health records from the TriNetX US Collaborative Network. Adults with ankylosing spondylitis (AS), psoriasis (PsO), or psoriatic arthritis (PsA) who newly initiated a JAKi or a TNFi between January 1, 2016, and December 31, 2023, were identified. Patients were stratified into JAKi and TNFi cohorts based on initial treatment exposure. Propensity score matching (1:1) was performed to balance baseline demographics, comorbidities, prior medication use, and laboratory values. Cox proportional hazards models were used to estimate hazard ratio (HR) and 95% confidence interval(CI) for the development of incident uveitis, with TNFi as the reference. Kaplan\u2013Meier analysis was conducted to compare the 9-year cumulative incidence of uveitis between cohorts. The primary outcome was incident uveitis following initiation of therapy, with follow-up extending up to nine years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 697,850 patients identified, 5,874 were included in each group after 1:1 propensity score matching. JAKi use was associated with a lower risk of incident uveitis compared with TNFi (HR = 0.630; 95% CI, 0.418\u20130.948). These findings remained consistent after further adjustment for comorbidities, medications, and laboratory data. Subgroup analyses showed a consistent protective association in older patients (\u2265 51 years: HR = 0.43, 95% CI = 0.24\u20130.79), White individuals (HR = 0.59, 95% CI = 0.38\u20130.93), and those with elevated inflammatory markers (CRP \u2265 3 mg\/L: HR = 0.50, 95% CI = 0.26\u20130.96; ESR \u2265 20 mm\/h: HR = 0.41, 95% CI = 0.19\u20130.87). The reduced risk persisted regardless of concomitant use of conventional synthetic DMARDs (with csDMARDs: HR = 0.50, 95% CI = 0.28\u20130.92; without csDMARDs: HR = 0.56, 95% CI = 0.33\u20130.94).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large-scale, real-world cohort study, JAKi therapy was associated with a significantly reduced risk of incident uveitis compared to TNFi therapy in patients with AS, PsO, or PsA. These findings suggest a potential role for JAKi in mitigating ocular inflammation in this population. Further prospective studies and randomized controlled trials are warranted to validate these results and inform future clinical guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1673970","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:28:22Z","timestamp":1761283702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei-Hsuan","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chiao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.emc.2021.08.005","article-title":"Spondyloarthritides","volume":"40","author":"Taitt","year":"2022","journal-title":"Emerg Med Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.08.002","article-title":"Uveitis and spondyloarthropathies","volume":"31","author":"Sharma","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.3390\/ijms24076463","article-title":"Uncovering the underworld of axial spondyloarthritis","volume":"24","author":"Del Vescovo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-\u03b1 in uveitis: from bench to clinic","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - the GO-EASY study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e001161","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2324400","DOI":"10.1155\/2021\/2324400","article-title":"Role of janus kinase (JAK) inhibitor in autoimmune ocular inflammation: A systematic review","volume":"2021","author":"Wen","year":"2021","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1439338","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors","volume":"46","author":"Yang","year":"2023","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-024-03331-0","article-title":"Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1419722","article-title":"From psoriasis to psoriatic arthritis: epidemiological insights from a retrospective cohort study of 74,046 patients","volume":"11","author":"Huo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e003038","DOI":"10.1136\/rmdopen-2023-003038","article-title":"COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs","volume":"9","author":"Tsai","year":"2023","journal-title":"RMD Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29188","article-title":"The risk assessment of uveitis after COVID-19 diagnosis: A multicenter population-based study","volume":"95","author":"Hsia","year":"2023","journal-title":"J Med Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.2045","article-title":"Assessing the uniformity of uveitis clinical concepts and associated ICD-10 codes across health care systems sharing the same electronic health records system","volume":"139","author":"McKay","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15099","article-title":"Risk of uveitis in autoimmune diseases patients treated with hydroxychloroquine: A population-based retrospective cohort study","volume":"27","author":"Bai","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1750-1172-7-57","article-title":"Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients","volume":"7","author":"Barisani-Asenbauer","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-4174-7","article-title":"Relevance of erythrocyte sedimentation rate and C-reactive protein in patients with active uveitis","volume":"257","author":"Groen-Hakan","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","article-title":"The effectiveness of adalimumab treatment for non-infectious uveitis","volume":"42","author":"Hasegawa","year":"2019","journal-title":"Immunol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.42788","article-title":"Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: A systematic review and network meta-analysis","volume":"76","author":"Bechman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00761-z","article-title":"Treatment of axial spondyloarthritis: an update","volume":"18","author":"Danve","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623725","article-title":"Uveitis: molecular pathogenesis and emerging therapies","volume":"12","author":"Egwuagu","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00954-6","article-title":"Pathogenesis and current therapies for non-infectious uveitis","volume":"23","author":"Wu","year":"2023","journal-title":"Clin Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-01763-8","article-title":"New pharmacotherapy options for noninfectious posterior uveitis","volume":"41","author":"Pleyer","year":"2021","journal-title":"Int Ophthalmol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:28:23Z","timestamp":1761283703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1673970"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1673970","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"article-number":"1673970"}}